George Washington and Minnesota universities-founded cell therapy developer Catamaran has raised cash to move two assets toward the clinic.

Catamaran Bio, a US-based cancer treatment developer founded out of University of Minnesota and George Washington University (GWU), launched yesterday with $42m of series A funding co-led by Sofinnova Partners and Lightstone Ventures. Takeda Ventures, a strategic investment arm of pharmaceutical firm Takeda, also took part in the round, as did SV Health Investors and…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.